Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program

Lexicon Pharmaceuticals (LXRX) PT Lowered to $3 at Citi

July 30, 2019 2:50 AM EDT

Citi analyst Yigal Nochomovitz lowered the price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $3.00 (from $15.00) while maintaining a Buy rating.

... More